Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 252004
                    [Title] => Treatment for Barrett’s crucial in preventing esophageal adenocarcinoma
                    [Summary] => 
(Conclusion)
After a mean follow-up of 45 months, 42 patients (40 percent) had no histological evidence of BE, 43 patients (41 percent) had no dysplasia, 14 patients (13 percent) had low-grade dysplasia, two patients (2 percent) had high-grade dysplasia and four patients (4 percent) developed cancer. Based on current estimates of cancer incidence in high-grade and low-grade dysplasia, 20 cancers would have been anticipated in this group versus the four that did occur (P<0.001).


                    [DatePublished] => 2004-05-31 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

        )

)

GASTROINTEST ENDOSC

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 252004
                    [Title] => Treatment for Barrett’s crucial in preventing esophageal adenocarcinoma
                    [Summary] => 
(Conclusion)
After a mean follow-up of 45 months, 42 patients (40 percent) had no histological evidence of BE, 43 patients (41 percent) had no dysplasia, 14 patients (13 percent) had low-grade dysplasia, two patients (2 percent) had high-grade dysplasia and four patients (4 percent) developed cancer. Based on current estimates of cancer incidence in high-grade and low-grade dysplasia, 20 cancers would have been anticipated in this group versus the four that did occur (P<0.001).


                    [DatePublished] => 2004-05-31 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

        )

)

abtest

Treatment for Barrett’s crucial in preventing esophageal adenocarcinoma

By YOUR DOSE OF MEDICINE | By Charles C. Chante MD | May 31, 2004 - 12:00am

(Conclusion) After a mean follow-up of 45 months, 42 patients (40 percent) had no histological evidence of BE, 43 patients (41 percent) had no dysplasia, 14 patients (13 percent) had low-grade dysplasia, two patients...

Opinion